日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Medication Use by Older Adults with Frailty: A Scoping Review

老年体弱者用药情况:范围综述

Sharma, Rishabh; Sharma, Tanaya; McCready-Branch, Brent; Chauhan, Arshia; Carter, Caitlin; Park, SooMin; Hudani, Imra; Choudhuri, Prapti; Patel, Tejal

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML

一项评估enasidenib联合风险适应性加用阿扎胞苷治疗新诊断的IDH2突变型急性髓系白血病疗效的研究

Sheng F Cai ,Ying Huang ,Jennie R Lance ,Hsiaoyin Charlene Mao ,Andrew J Dunbar ,Samantha N McNulty ,Todd Druley ,Yan Li ,Maria R Baer ,Wendy Stock ,Tibor Kovacsovics ,William G Blum ,Gary J Schiller ,Rebecca L Olin ,James M Foran ,Mark Litzow ,Tara Lin ,Prapti Patel ,Matthew C Foster ,Michael Boyiadzis ,Robert H Collins ,Jordan Chervin ,Abigail Shoben ,Jo-Anne Vergilio ,Nyla A Heerema ,Leonard Rosenberg ,Timothy L Chen ,Ashley O Yocum ,Franchesca Druggan ,Sonja Marcus ,Mona Stefanos ,Brian J Druker ,Alice S Mims ,Uma Borate ,Amy Burd ,John C Byrd ,Ross L Levine ,Eytan M Stein

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

抑制致癌性IDH突变的非竞争性抑制可导致获得性耐药。

Junhua Lyu,Yuxuan Liu,Lihu Gong,Mingyi Chen,Yazan F Madanat,Yuannyu Zhang,Feng Cai,Zhimin Gu,Hui Cao,Pranita Kaphle,Yoon Jung Kim,Fatma N Kalkan,Helen Stephens,Kathryn E Dickerson,Min Ni,Weina Chen,Prapti Patel,Alice S Mims,Uma Borate,Amy Burd,Sheng F Cai,C Cameron Yin,M James You,Stephen S Chung,Robert H Collins,Ralph J DeBerardinis,Xin Liu,Jian Xu

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

对 CD3xCD123 双特异性抗体 APVO436 在复发/难治性 AML 和 MDS(对 HMA 或 Venetoclax 联合 HMA 耐药)中的药效学和单药活性进行事后分析

Justin Watts ,Tara L Lin ,Alice Mims ,Prapti Patel ,Cynthia Lee ,Anoush Shahidzadeh ,Paul Shami ,Elizabeth Cull ,Christopher R Cogle ,Eunice Wang ,Fatih M Uckun

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

接受 CD3xCD123 双特异性抗体 APVO436 治疗的复发/难治性 AML 或 MDS 患者的细胞因子释放综合征风险、特征和生物标志物

Fatih M Uckun, Justin Watts, Alice S Mims, Prapti Patel, Eunice Wang, Paul J Shami, Elizabeth Cull, Cynthia Lee, Christopher R Cogle, Tara L Lin